Quality of life measurement in rosacea. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa-Reference-Cited by-同舟云学术

Quality of life measurement in rosacea. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa

Published:2023-02-06 Issue:5 Volume:37 Page:954-964
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Chernyshov P. V.¹^ORCID,Finlay A. Y.²^ORCID,Tomas‐Aragones L.³,Steinhoff M.⁴⁵⁶⁷⁸,Manolache L.⁹,Pustisek N.¹⁰,Dessinioti C.¹¹^ORCID,Svensson A.¹²^ORCID,Marron S. E.¹³,Bewley A.¹⁴¹⁵^ORCID,Salavastru C.¹⁶,Dréno B.¹⁷,Suru A.¹⁶,Koumaki D.¹⁸^ORCID,Linder D.¹⁹^ORCID,Evers A. W. M.²⁰,Abeni D.²¹,Augustin M.²²^ORCID,Salek S. S.²³^ORCID,Nassif A.²⁴,Bettoli V.²⁵^ORCID,Szepietowski J. С.²⁶^ORCID,Zouboulis C. C.²⁷^ORCID

Affiliation:

1. Department of Dermatology and Venereology National Medical University Kiev Ukraine

2. Division of Infection and Immunity, School of Medicine Cardiff University Cardiff UK

3. Department of Psychology University of Zaragoza Zaragoza Spain

4. Department of Dermatology and Venereology Hamad Medical Corporation Doha Qatar

5. Dermatology Institute, Academic Health System Hamad Medical Corporation Doha Qatar

6. Translational Research Institute, Academic Health System Hamad Medical Corporation Doha Qatar

7. Weill Cornell Medicine‐Qatar Doha Qatar

8. Medical School Qatar University Doha Qatar

9. Dermatology, Dali Medical Bucharest Romania

10. Children's Hospital Zagreb Zagreb Croatia

11. Department of Dermatology Andreas Syggros Hospital, University of Athens Athens Greece

12. Department of Dermatology and Venereology Skane University Hospital Malmö Sweden

13. Department of Dermatology Royo Villanova Hospital, Aragon Psychodermatology Research Group (GAI+PD) Zaragoza Spain

14. Whipps Cross University Hospital London UK

15. The Royal London Hospital London UK

16. Department of Paediatric Dermatology Colentina Clinical Hospital, “Carol Davila” University of Medicine and Pharmacy Bucharest Romania

17. INSERM, Immunology and New Concepts in ImmunoTherapy, INCIT Nantes Université, Univ Angers Nantes France

18. Department of Dermatology and Venereology University Hospital of Heraklion Heraklion, Crete Greece

19. University Clinic for Medical Psychology and Psychotherapy, Medical University of Graz Graz Austria

20. Institute of Psychology, Health, Medical, and Neuropsychology Unit Leiden University Leiden The Netherlands

21. Clinical Epidemiology Unit, IDI‐IRCCS Rome Italy

22. Institute for Health Services Research in Dermatology and Nursing (IVDP) University Medical Center Hamburg‐Eppendorf Hamburg Germany

23. School of Life & Medical Sciences University of Hertfordshire Hatfield UK

24. Institut Pasteur Paris France

25. Department of Medical Sciences, Section of Dermatology University of Ferrara Ferrara Italy

26. Department of Dermatology Wroclaw Medical University Wroclaw Poland

27. Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg Dessau Germany

Abstract

AbstractThe European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient‐Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa (ARHS) do not recommend the use of any generic instrument as a single method of Health Related (HR) QoL assessment in rosacea, except when comparing quimp (quality of life impairment) in rosacea patients with that in other non‐dermatologic skin diseases and/or healthy controls. The EADV TFs on QoL and Patient‐Oriented Outcomes and ARHS recommend the use of the dermatology‐specific HRQoL instrument the Dermatology Life Quality Index (DLQI) and the rosacea‐specific HRQoL instrument RosaQoL in rosacea patients. The DLQI minimal clinically important difference may be used as a marker of clinical efficacy of the treatment and DLQI score banding of 0 or 1 corresponding to no effect on patients' HRQoL could be an important treatment goal. This information may be added to consensuses and guidelines for rosacea.

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.18918

Reference126 articles.

1. Clinical, Cellular, and Molecular Aspects in the Pathophysiology of Rosacea

2. Rosacea: Current state of epidemiology

3. Burden of disease: the psychosocial impact of rosacea on a patient's quality of life;Huynh TT;Am Heal Drug Benefits,2013

4. Rosacea as a Disease of Cathelicidins and Skin Innate Immunity

5. Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of life measurement in assessing treatment effectiveness in urticaria: European experts position statement;International Journal of Dermatology;2024-07-04

2. Elevated Specific Pro-Inflammatory Cytokines in Peripheral Circulation Indicate an Increased Risk of Anxiety and Depression in Rosacea;Journal of Inflammation Research;2024-07

3. Quality of life measurement in urticaria: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient‐Oriented Outcomes and Urticaria and Angioedema;Journal of the European Academy of Dermatology and Venereology;2024-06-10

4. Efficacy and safety of botulinum toxin for rosacea with positive impact on quality of life and self‐esteem;International Journal of Dermatology;2024-01-21

5. Bullying in persons with skin diseases;Journal of the European Academy of Dermatology and Venereology;2023-12-07